tirzepatide hfpef trial SUMMIT: a 'Huge Win' for Patients With Obesity An Observational Study of Cardiovascular

500+ success stories

As of November 2023, Mounjaro has been approved as a weight loss treatment in the UK

Lose 15-20% body weight

Purpose of Review This review will summarize the most contemporary trials for glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and present guidance on management and recommendations on adjunctive tapering of insulin in patients with insulin-dependent diabetes mellitus, which we term de-insulinization. Recent Findings GLP1-RA and SGLT2-i are the principal classes of diabetes medications evidencing cardiovascular benefit

The Beyond-Use Date (BUD) for compounded semaglutide indicates how long the medication remains stable and safe to use, based on factors like formulation and storage